

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10	
EV724615435US	September 21, 2005
Express Mail Label Number	Date of Deposit

IC20 Rec'd PCT/PTO 21 SEP 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

AITKEN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP04/003518

FILED: 2 APRIL 2004

U.S. APPLICATION NO: Not Yet Assigned

35 USC §371 DATE:

FOR: COMBINATIONS COMPRISING ANTI-EPILEPTIC DRUGS FOR THE  
TREATMENT OF NEUROLOGICAL DISORDERS**MS: Amendment**

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP04/003518, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis  
Corporate Intellectual Property  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-7960  
Date: 21 Sep. 2005

Respectfully submitted,



Edward J. Wilusz, Jr.  
Attorney for Applicants  
Reg. No. 52,370

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

PCT-3500141

APPLICATION NO.

Not Yet Assigned

APPLICANT

AITKEN ET AL.

FILING DATE

Group

JC20 Rec'd PCT/PTO 21 SEP 2009

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
/PEZ/	AA	5,095,033	3/10/92	Rene Levy et al.			
/PEZ/	AB	3,489,836	1/13/70	Wilson Shaw Waring			
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	WO 89/05642	6/29/89	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	GB 864 536	4/5/61	Great Britain			<input type="checkbox"/>	<input type="checkbox"/>
	AO	EP 0 037 443	2/8/93	EPO			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 84/38778	6/7/84	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 82/09915	1/17/82	WIPO			<input type="checkbox"/>	<input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	DATABASE WPI Section Ch, Week 200066 Derwent Publications Ltd., London, GB; Class B05, AN 2000-073134 XP002291965 & CN 1 205 689 A (WANG X) 13 September 2000 (2000-09-13)
	AS	Ernst Mutschler: "Arzneimittelwirkungen - Lehrbuch der Pharmakologie und Toxikologie" 1997, Wissenschaftliche Verlagsgesellschaft MbH Stuttgart, Stuttgart, XP002291963 page 252 - page 260 in particular p. 260
	AT	Mark H. Beers, M.D., Robert Berkow, M.D.: "The Merck Manual" 1999, Merck Research Laboratories, Whitehouse Station, N.J., XP002291964 page 1406 - page 1408

EXAMINER

/Paul Zarek/

DATE CONSIDERED

07/22/2008

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

FORM PTO-1449  
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.

PNV-63001A

APPLICATION NO.

Not Yet Assigned

APPLICANT

AITKEN ET AL.

FILING DATE

Group

EXAMINER  
INITIAL

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Dam M: "Summing Up Of The Success So Far Gained Through Choice Of Drugs Or Combinations Of Drugs" Acta Neurologica Scandinavica Supplementum, vol. 69, no. 99, 1984, pages 19-22, XP009035076 & 3RD Workshop On Memory Functions, Gothenburg, FEB. 4-6, 1983. ACTA Neurol Scand Suppl. ISSN: 0065-1427
DB	Deckers C L P et al: "Selection of antiepileptic drug polytherapy based on mechanisms of action: The evidence reviewed" Epilepsia 2000 United States, vol. 41, no. 11, 2000, pages 1364-1374, XP009035157 ISSN: 0013-9580
DC	Zarnowski Tomasz et al: "NBQX: A selective AMPA antagonist enhances antiepileptic properties of common anticonvulsant drugs against maximal electroshock in mice" Polish Journal Of Pharmacology And Pharmacy, vol. 44, no. SUPPL., 1992, pages 258-259, XP009035158 & XI Congress Of The Polish Pharmacological Society And Of The German Society Of Pharmacology And Toxi; Gdansk, Poland; September 16-19, 1992 ISSN: 0301- 0244
DD	Borowicz Kinga K ET AL: "Interaction of GYKI 52466, a selective non-competitive antagonist of AMPA/kainate receptors, with conventional antiepileptic drugs in amygdala-kindled seizures in rats" Polish Journal Of Pharmacology, vol. 53, no. 2, March 2001 (2001-03), pages 101-108, XP009035159 ISSN: 1230-6002
DE	Borowicz Kinga K et al: "The non-competitive AMPA/kainate receptor antagonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepileptics" European Journal Of Pharmacology, vol. 281, no. 3, 1995, pages 319-326, XP002292362 ISSN: 0014-2999
DF	Swiader Mariusz et al: "Influence of LY 300164, an AMPA/kainate receptor antagonist upon the anticonvulsant action of antiepileptic drugs against aminophylline-induced seizures in mice." Polish Journal Of Pharmacology, vol. 55, no. 1, January 2003 (2003-01), pages 103-107, XP009035160 ISSN: 230-6002
DG	Czuczwar S J et al: "LY 300164, a novel antagonist of AMPA/kainite receptors, potentiates the anticonvulsive activity of antiepileptic drugs" European Journal Of Pharmacology 1998 Netherlands, vol. 359, no. 2-3, 1998, pages 103-109, XP002292363 ISSN: 0014-2999
DH	Auberson Y P ET AL: "N-phosphonoalkyl-5- aminomethylquinoxaline -2,3-diones: in vivo active AMPA and NMDA(glycine) antagonists" Bioorganic & Medicinal Chemistry Letters, Oxford, GB, vol. 9, no. 2, 18 January 1999 (1999-01-18), pages 249-254, XP004152611 ISSN: 0960-894X
DI	
DJ	
DK	
DL	
DM	
DN	

EXAMINER

DATE CONSIDERED

(Use several sheets if necessary)

ATTY. DOCKET NO.

PN/4-33001A

APPLICATION NO.

No. 6 Assigned

APPLICANT

AITKEN ET AL.

FILING DATE

Group

**10/550381**

**JC20 Rec'd PCT/PTO 21 SEP 2005**

\*EXAMINER: Initial of reference

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	CA	WO 98/17692	4/30/98	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	CB	WO 03/042182	5/22/03	WIPO			<input type="checkbox"/>	<input type="checkbox"/>
	CC	CN 1265889	9/13/00	China			<input type="checkbox"/>	<input type="checkbox"/>
	CD						<input type="checkbox"/>	<input type="checkbox"/>
	CE						<input type="checkbox"/>	<input type="checkbox"/>
	CF						<input type="checkbox"/>	<input type="checkbox"/>
	CG						<input type="checkbox"/>	<input type="checkbox"/>
	CH						<input type="checkbox"/>	<input type="checkbox"/>
	CI						<input type="checkbox"/>	<input type="checkbox"/>
	CJ						<input type="checkbox"/>	<input type="checkbox"/>
	CK						<input type="checkbox"/>	<input type="checkbox"/>
	CL						<input type="checkbox"/>	<input type="checkbox"/>
	CM						<input type="checkbox"/>	<input type="checkbox"/>
	CN						<input type="checkbox"/>	<input type="checkbox"/>
	CO						<input type="checkbox"/>	<input type="checkbox"/>
	CP						<input type="checkbox"/>	<input type="checkbox"/>
	CQ						<input type="checkbox"/>	<input type="checkbox"/>
	CR						<input type="checkbox"/>	<input type="checkbox"/>
	CS						<input type="checkbox"/>	<input type="checkbox"/>
	CT						<input type="checkbox"/>	<input type="checkbox"/>
	CU						<input type="checkbox"/>	<input type="checkbox"/>
	CV						<input type="checkbox"/>	<input type="checkbox"/>
	CW						<input type="checkbox"/>	<input type="checkbox"/>
	CX						<input type="checkbox"/>	<input type="checkbox"/>
	CY						<input type="checkbox"/>	<input type="checkbox"/>
	CZ						<input type="checkbox"/>	<input type="checkbox"/>

**EXAMINER**

**DATE CONSIDERED**

\*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.